Recent Updates
Recently added Catalysts
ETON Positive Sentiment Score: 70/100

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

Monday, November 24, 2025 1 min read
Key Takeaway: Eton Pharmaceuticals announced its participation in the Piper Sandler 37th Annual Healthcare Conference scheduled for December 4, 2025, in New York City. Members of the executive leadership team will host a fireside chat, providing an opportunity for investors to engage with the company. Eton is dedicated to developing treatments for rare diseases, with multiple commercial products and candidates in late-stage development, highlighting its commitment to innovation in the pharmaceutical space.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eton Pharmaceuticals is focusing on rare disease treatments, showcasing innovation.
  • The company is actively engaging with investors through events like the Piper Sandler Conference.
  • Eton has multiple commercial products and late-stage candidates, indicating a strong pipeline.

Full Press Release Details

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in NYC as follows:
DATE: Thursday, December 4, 2025
LOCATION: Lotte New York Palace
To schedule a 1x1 meeting with the Company, please contact your Piper Sandler institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Lisa M. Wilson, In-Site Communications, Inc.
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.

Frequently Asked Questions

When is Eton Pharmaceuticals' fireside chat scheduled?

The fireside chat is on December 4, 2025.

Where is the Piper Sandler Healthcare Conference taking place?

It will be held at the Lotte New York Palace.

What focus does Eton Pharmaceuticals have?

Eton specializes in treatments for rare diseases.

How many commercial products does Eton have?

Eton has eight commercial rare disease products.

What additional candidates is Eton developing?

Eton has five late-stage product candidates in development.

Tags: ETON Viatris Investor Conferences Healthcare Eton Pharmaceuticals rare diseases Piper Sandler healthcare conference clinical development
Last updated: Nov 24, 2025